# CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

> **NCT06947460** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing GoBroad Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Refractory Lupus Nephritis
- Systemic Sclerosis
- Primary Sjogren's Syndrome Combined With Pulmonary Hypertension

## Interventions

- **DRUG:** CD19-BCMA CAR-T cells infusion

## Key facts

- **NCT ID:** NCT06947460
- **Lead sponsor:** Beijing GoBroad Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-18
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-07-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06947460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06947460, "CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06947460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*